Cite

    Kievit, W., Fransen, J., Adang, E. M., Kuper, H. H., Jansen, T. L., De Gendt, C. M. A., De Rooij, D. J. R. A. M., Brus, H. L. M., van de Laar, M. A. F. J., & Van Riel, P. C. L. M. (2009). evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Annals of the rheumatic diseases, 68(6), 844–849. http://access.bl.uk/ark:/81055/vdc_100137791897.0x000061